Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Usana Health Sciences (USNA) EBITDA Margin (2016 - 2026)

Usana Health Sciences has reported EBITDA Margin over the past 17 years, most recently at 3.48% for Q2 2026.

  • Quarterly EBITDA Margin fell 21.0% to 3.48% in Q2 2026 from the year-ago period, while the trailing twelve-month figure was 1.72% through Apr 2026, down 177.0% year-over-year, with the annual reading at 1.86% for FY2026, 200.0% down from the prior year.
  • EBITDA Margin was 3.48% for Q2 2026 at Usana Health Sciences, up from 0.35% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 10.54% in Q4 2023 and troughed at 3.09% in Q3 2025.
  • The 5-year median for EBITDA Margin is 4.32% (2023), against an average of 4.72%.
  • The largest YoY upside for EBITDA Margin was 420bps in 2024 against a maximum downside of -1265bps in 2024.
  • A 5-year view of EBITDA Margin shows it stood at 8.78% in 2022, then increased by 20bps to 10.54% in 2023, then tumbled by -120bps to 2.11% in 2024, then tumbled by -46bps to 3.09% in 2025, then surged by 213bps to 3.48% in 2026.
  • Per Business Quant, the three most recent readings for USNA's EBITDA Margin are 3.48% (Q2 2026), 0.35% (Q1 2026), and 3.09% (Q3 2025).